Fibrinogen

• 

  Subject Areas on Research

  • A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. 
  • A comparative study of crosslinked and noncrosslinked fibrin from the major classes of vertebrates. 
  • A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. 
  • A multidimensional approach for detecting species patterns in Malagasy vertebrates. 
  • A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. 
  • Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. 
  • Actions of thrombin in the interstitium. 
  • Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients. 
  • Adhesion of Blood Plasma Proteins and Platelet-rich Plasma on l-Valine-Based Poly(ester urea). 
  • Alterations in viscosity and filterability of whole blood and blood cell subpopulations in diabetic cats. 
  • Alterations of fibrinogen structure in human disease. 
  • Anesthetic concerns for patients with coagulopathy. 
  • Antiplatelet effects of a novel antianginal agent, nicorandil. 
  • Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. 
  • ApoA-I induced CD31 in bone marrow-derived vascular progenitor cells increases adhesion: implications for vascular repair. 
  • Assessments of thrombogenicity by three in vitro techniques. Student Research Award in the Undergraduate, Master Candidate, or Health Science Degree Candidate Category, 21st annual meeting of the Society for Biomaterials, San Francisco, CA, March 18-22, 1995. 
  • Association of electrocardiographic left ventricular hypertrophy with incident cardiovascular disease in Japanese older hypertensive patients. 
  • Atherosclerosis and restenosis: an inflammatory issue. 
  • Binding of human plasminogen to basement-membrane (type IV) collagen. 
  • Bleeding and management of coagulopathy. 
  • Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness. 
  • C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 
  • C-reactive protein, fibrinogen, and cardiovascular disease prediction. 
  • Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity. 
  • Cardiorespiratory biomarker responses in healthy young adults to drastic air quality changes surrounding the 2008 Beijing Olympics. 
  • Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. 
  • Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. 
  • Chronic cicatrizing conjunctivitis in a patient with epidermolysis bullosa acquisita. 
  • Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. 
  • Clinical implications of systemic inflammatory response syndrome following thoracic aortic stent-graft placement. 
  • Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. 
  • Clinical utility of erythrocyte sedimentation rate and plasma protein analysis in the elderly. 
  • Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. 
  • Coagulation parameters in copperhead compared to other Crotalinae envenomation: secondary analysis of the F(ab')2 versus Fab antivenom trial. 
  • Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. 
  • Coagulopathy in COVID-19. 
  • Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog. 
  • Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. 
  • Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. 
  • Concentration of protein in fibrin fibers and fibrinogen polymers determined by refractive index matching. 
  • Control of Intestinal Inflammation, Colitis-Associated Tumorigenesis, and Macrophage Polarization by Fibrinogen-Like Protein 2. 
  • Correlation between quantitative left atrial spontaneous echocardiographic contrast and intact fibrinogen levels in mitral stenosis. 
  • Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers. 
  • Cross-linking of fibrin by fibrin=stabilizing factor. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Cryoprecipitate therapy. 
  • Defining Potential Vaccine Targets of Haemophilus ducreyi Trimeric Autotransporter Adhesin DsrA. 
  • Disseminated intravascular coagulation (DIC): an approach. 
  • Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. 
  • Early cryoprecipitate for trauma patients is feasible, but will it improve outcome? 
  • Electron microscopy of fibrinogen, its plasmic fragments and small polymers. 
  • Electron microsocpy of plasmic fragments of human fibrinogen as related to trinodular structure of the intact molecule. 
  • Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. 
  • Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. 
  • Evaluation of peritoneal fluid following intestinal resection and anastomosis in horses. 
  • Evolution of the tenascin family--implications for function of the C-terminal fibrinogen-like domain. 
  • Experimental transfusion reactions and disseminated intravascular coagulation produced by incompatible plasma in monkeys. 
  • Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy. 
  • Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. 
  • Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 
  • Fibrin assembly: a comparison of electron microscopic and light scattering results. 
  • Fibrinogen and bleeding: old molecule--new ideas. 
  • Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. 
  • Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. 
  • Fibrinogen binding is affected by amino acid substitutions in C-terminal repeat region of fibronectin binding protein A. 
  • Fibrinogen content of low-volume cryoprecipitate. 
  • Fibrinogen kinetics in patients with neoplastic disease. 
  • Fibrinogen may mediate the association between long sleep duration and coronary heart disease. 
  • Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding. 
  • Fibrinolysis and fibrinogenolysis by Val442-plasmin. 
  • Fibronectin molecule visualized in electron microscopy: a long, thin, flexible strand. 
  • Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. 
  • Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. 
  • Graft-v-host disease is associated with autoimmune-like thrombocytopenia. 
  • Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. 
  • Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. 
  • Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin neutralization by recombinant platelet factor 4 and protamine. 
  • Higher mortality in pediatric and adult trauma patients with traumatic coagulopathy, using age-adjusted diagnostic criteria. 
  • Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin. 
  • How I use fibrinogen replacement therapy in acquired bleeding. 
  • Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. 
  • Hypercoagulable states in cardiovascular disease. 
  • Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. 
  • Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system. 
  • Impact of fibrinogen levels on angiographic progression and 12-year survival in the armed forces regression study. 
  • Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). 
  • In reply. 
  • In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. 
  • In-utero epigenetic factors are associated with early-onset myopia in young children. 
  • Increased glomerular deposits of von Willebrand factor in chronic, but not acute, rejection of primate renal allografts. 
  • Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. 
  • Injury-induced changes in liver specific transcription factors HNF-1α and HNF-4α. 
  • Insignificant blood damage in calves with a total artificial heart up to six months. 
  • Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery? 
  • Isolation and characterization of an acquired antithrombin antibody. 
  • Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. 
  • LOCALIZATION OF IMMUNOGLOBULINS IN CHRONIC THYROIDITIS. 
  • Lateral packing of protofibrils in fibrin fibers and fibrinogen polymers. 
  • Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. 
  • Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. 
  • Measurement of fibrinogen degradation products. 
  • Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Modification of integrin-mediated cell attachment to substrata by serine proteinases in the presence and absence of divalent cations. 
  • Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. 
  • Multicenter Evaluation of the Quantra QPlus System in Adult Patients Undergoing Major Surgical Procedures. 
  • Nontoxic nerve guide tubes support neovascular growth in transected rat optic nerve. 
  • Obesity-related coagulation changes in pregnancy. 
  • Orthopedic Surgery Triggers Attention Deficits in a Delirium-Like Mouse Model. 
  • Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. 
  • Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes. 
  • Periodontal health improves systemic inflammatory and haemostatic status in subjects with coronary heart disease. 
  • Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. 
  • Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy. 
  • Physical activity, television viewing time, and retinal vascular caliber. 
  • Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. 
  • Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. 
  • Polyimides as biomaterials: preliminary biocompatibility testing. 
  • Poor oral health is associated with coronary heart disease and elevated systemic inflammatory and haemostatic factors. 
  • Postpartum hemorrhage management in 2012: predicting the future. 
  • Postpartum hemorrhage: when uterotonics and sutures fail. 
  • Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. 
  • Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3. 
  • Predicting and treating coagulopathies after cardiopulmonary bypass in children. 
  • Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP across Framingham risk categories: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. 
  • Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery. 
  • Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. 
  • Quantitative assessment of fibrinogen cross-linking by epsilon aminocaproic acid in patients with end-stage liver disease. 
  • Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results. 
  • Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. 
  • Reduction in blood transfusion in a cohort of infants having cardiac surgery with cardiopulmonary bypass after instituting a goal-directed transfusion policy. 
  • Role of fibrinopeptide B in early atherosclerotic lesion formation. 
  • S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. 
  • Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. 
  • Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. 
  • Subunit structure of fragment D from fibrinogen and cross-linked fibrin. 
  • Superficial migratory thrombophlebitis and factor XII deficiency. 
  • Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials. 
  • The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. 
  • The clearance of human fibrinogen fragments D1, D2, D3 and fibrin fragment D1 dimer in mice. 
  • The diagnosis of pulmonary embolism. 
  • The effect of fibrin polymerization inhibitors on quantitative measurements of plasma fibrinogen. 
  • The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. 
  • The effect of plasmin on the subunit structure of human fibrinogen. 
  • The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). 
  • The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. 
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2. 
  • The role of ligand-ligand interactions in competition by fibrinogen and fibrin degradation products for fibrinogen binding to human platelets. 
  • The role of soluble components in ambient fine particles-induced changes in human lungs and blood. 
  • The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. 
  • The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). 
  • Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. 
  • Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. 
  • Use of Earlier-Reported Rotational Thromboelastometry Parameters to Evaluate Clotting Status, Fibrinogen, and Platelet Activities in Postpartum Hemorrhage Compared to Surgery and Intensive Care Patients. 
  • Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of human fibrinogen concentrate during proximal aortic reconstruction with deep hypothermic circulatory arrest. 
  • Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Implications for reducing donor exposure. 
  • Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. 
  • Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. 
  • Zwitterionic amino acid-based Poly(ester urea)s suppress adhesion formation in a rat intra-abdominal cecal abrasion model. 
• 

  Keywords of People

  • Erickson, Harold Paul, James B. Duke Distinguished Professor of Cell Biology, Cell Biology
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Hoffman, Maureane, Professor of Pathology, Immunology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma